Chiusura precedente | 51,72 |
Aperto | 51,07 |
Denaro | N/D x N/D |
Lettera | N/D x N/D |
Min-Max giorno | 51,07 - 51,07 |
Intervallo di 52 settimane | 43,31 - 65,36 |
Volume | |
Media Volume | 26 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | 2,07 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | 01 ago 2024 - 05 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Wilmington, DE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its third quarter 2023 financial results on Tuesday, November 7, 2023 at 8:00 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section. Conference call/Webca
Creating a high-growth, global reconstruction leader with ~$1 billion in annual revenueAttractive margin profile and meaningful synergies expected to increase profitability Wilmington, DE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”), an innovation-driven, medical technology growth company, today announced a definitive agreement to acquire LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic leader focused on restoring motion through
New solutions in Percutaneous and Open Bunion procedures, External Fixation, and Patient Specific Instrumentation, will be featured as part of the company’s growing evidence based, high tech portfolio. Enovis Foot & Ankle at AOFAS 2023 Products featured by Enovis™ Foot & Ankle at the AOFAS Annual Meeting Wilmington, DE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology company, announced it will showcase new products from its rec